After two FDA rejections against China-made cancer immunotherapies this year, another Chinese pharma hopes it has the data to crack the agency’s doors open. But one major uncertainty remains.
Thursday, Jiangsu Hengrui Medicine said a global phase 3 trial of its PD-1 inhibitor camrelizumab and VEGFR inhibitor apatinib, also known as rivoceranib, has hit its goals in newly diagnosed patients of liver cancer. The combination topped Bayer’s Nexavar at extending patients’ lives and preventing disease progression or death, Hengrui said in a filing (PDF, Chinese) to the Shanghai Stock Exchange.
